NCT05740800已完成不适用
Patient Care Needs and the Decision-Making Experience of Patients With Cancer and Family Caregivers Regarding Immunotherapy: A Qualitative and Quantitative Mixed Methods Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 184
- 试验地点
- 1
- 主要终点
- Supportive Care Needs Survey
研究概览
简要总结
Immunotherapy is currently a crucial cancer treatment option. Despite the development of new cancer treatment, patients and their family caregivers still experience complex psychological feelings and challenges about the effectiveness of immunotherapy, financial burden, and treatment related side effects which reflect the problems related to decision-making and the supportive care needs.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 20 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •20 years old and above.
- •Patients diagnosed with cancer by a physician.
- •The patient has a known condition and has received immunotherapy.
- •Those who have received at least 1 time immunotherapy, including: receiving a single drug or immunotherapy combined with other treatment.
排除标准
- •Patients with mental illness.
- •Confused and unable to communicate verbally or in writing to complete the research interviews.
- •Those who are reluctant to accept interviews and participate in research surveys.
- •Family caregivers
- •Inclusion Criteria:
- •20 years old and above.
- •Live with the patient and spend the most time caring for the patient.
- •The primary family caregiver is identified by the patient.
- •Exclusion Criteria:
- •Caregivers with mental illness.
结局指标
主要结局
Supportive Care Needs Survey
时间窗: 1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
Patients' and family caregivers' supportive care needs will be measured by Supportive Care Needs Survey(SCNS) .It is a 5-Point Likert Scale,higher scores mean more care needs.
次要结局
- CollaboRATE scale and SURE scale(1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.)
- Physical and Psychological Symptoms Scale(1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.)
- Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT)(1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.)
- Common Terminology Criteria for Adverse Events (CTCAE) version 5.0(1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T CellsDiffuse Large B-cell Lymphoma (DLBCL)CAR-T Cells TreatmentNCT05532761Hospices Civils de Lyon30
招募中
不适用
QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient ManagementSolid TumorHematologic CancerNCT05626764Hospices Civils de Lyon3,000
进行中（未招募）
不适用
Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory DrugsCancerNCT03984318Gustave Roussy, Cancer Campus, Grand Paris1,240
已完成
不适用
Shared Decision Making on Immunotherapy in OncologyPatient Decision AidTreatment As UsualNCT04240717University Hospital Heidelberg126
进行中（未招募）
不适用
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With CancerMacrophage Activation SyndromePrimary Hemophagocytic LymphohistiocytosisNCT03827343National Cancer Institute (NCI)500